文献速递免疫规划传染病防控与疫情报告

荷兰5岁以下儿童中10价肺炎球菌结合疫苗对侵袭性肺炎球菌疾病的影响和效果

Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
PubMed 文献 · Vaccine · 2020-11-24

荷兰2011年将PCV7替换为PCV10,基于2004–2019年全国监测数据比较替换前后侵袭性肺炎球菌疾病(IPD)发病率,并用间接队列法估计疫苗效果。结果显示PCV10额外血清型IPD下降93%,总体疫苗效果91%,非PCV10 IPD无显著上升,对19A型交叉保护无统计学意义。

要点

  • PCV10替换PCV7后,疫苗额外血清型IPD发病率下降93%。
  • PCV10对5岁以下儿童IPD总体疫苗效果为91%(95%CI 67;97)。
  • 非PCV10血清型IPD呈非显著上升,对19A型交叉保护无统计学意义。

核心结论

  • PCV10对荷兰5岁以下儿童IPD具有高度保护效果。
  • 从PCV7替换为PCV10后血清型替换有限。
  • 未发现PCV10对19A血清型IPD有显著交叉保护的证据。

研究设计与样本

  • 纳入2004–2019年全国监测系统报告的5岁以下儿童IPD病例。
  • 比较PCV10引入后6–8年(2017–2019)与替换前两年(2009–2011)的IPD发病率以评估影响。
  • 采用间接队列法估计疫苗效果,比较PCV10血清型IPD病例与非PCV10 IPD对照的接种状态(至少两剂)。

主要发现

  • 总体发病率从2009–2011年的8.7/10万(n=162)降至2017–2019年的7.3/10万(n=127),IRR 0.83(95%CI 0.66;1.05)。
  • PCV10额外血清型所致IPD下降93%(IRR 0.07,95%CI 0.02;0.23)。
  • 非PCV10 IPD发病率呈非显著上升(IRR 1.25,95%CI 0.96;1.63)。
  • 231例符合PCV10接种条件的IPD病例中,总体疫苗效果为91%(95%CI 67;97),按性别或诊断年龄无差异。
  • 对非PCV10血清型19A IPD的疫苗效果为28%(95%CI -179;81),无统计学意义。

临床怎么用

  • 监测数据支持PCV10在5岁以下儿童中持续使用以预防IPD。
  • 需关注非PCV10血清型IPD的潜在上升趋势。
  • 对19A型IPD的防护不能依赖PCV10的交叉保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2011, the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) in the Netherlands. We report on impact and effectiveness against invasive pneumococcal disease (IPD) in children aged under 5 years by switching from PCV7 to PCV10. METHOD: We included IPD cases between 2004 and 2019 in children aged < 5 years reported via the national surveillance system. To assess the impact of the PCV10 vaccination program we compared IPD incidence 6-8 years after PCV10 introduction (2017-2019) to the two years just before the switch to PCV10 (2009-2011). We estimated vaccine effectiveness (VE) using the indirect cohort method, comparing vaccination status (at least two vaccine doses) in IPD-cases caused by PCV10 serotypes (cases) to non-PCV10 IPD cases (controls), in children eligible for PCV10. RESULTS: The overall incidence decreased from 8.7 (n = 162) in 2009-2011 to 7.3 per 100.000 (n = 127) in 2017-2019 (Incidence rate ratio (IRR) 0.83, 95%CI: 0.66; 1.05). IPD caused by the additional serotypes included in PCV10 declined by 93% (IRR 0.07, 95%CI: 0.02; 0.23). Incidence of non-PCV10 IPD showed a non-significant increase (IRR 1.25, 95%CI: 0.96; 1.63). Among 231 IPD-cases eligible for PCV10, the overall VE was 91% (95%CI: 67; 97) and did not differ by sex or age at diagnosis. Effectiveness against non-PCV10 serotype 19A IPD was non-significant with an estimate of 28% (95%CI:-179; 81). CONCLUSION: PCV10 is highly effective in protecting against IPD in Dutch children under 5 years with limited serotype replacement after switching from PCV7 to PCV10. We found no evidence for significant cross-protection of PCV10 against 19A serotype IPD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Peckeu L, van der Ende A, de Melker HE, et al. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands. Vaccine. 2020. PMID: 33243632. doi:10.1016/j.vaccine.2020.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。